vs

Side-by-side financial comparison of NEOGENOMICS INC (NEO) and VIRTUS INVESTMENT PARTNERS, INC. (VRTS). Click either name above to swap in a different company.

VIRTUS INVESTMENT PARTNERS, INC. is the larger business by last-quarter revenue ($208.0M vs $186.7M, roughly 1.1× NEOGENOMICS INC). VIRTUS INVESTMENT PARTNERS, INC. runs the higher net margin — 16.3% vs -57.9%, a 74.1% gap on every dollar of revenue. On growth, NEOGENOMICS INC posted the faster year-over-year revenue change (11.1% vs -10.9%). Over the past eight quarters, NEOGENOMICS INC's revenue compounded faster (6.5% CAGR vs -3.2%).

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.

Virtus Investment Partners, Inc. is an American company which operates as a multi-manager asset management business, comprising a number of individual affiliated managers, each having its own investment process and brand, and the services of unaffiliated sub advisers.

NEO vs VRTS — Head-to-Head

Bigger by revenue
VRTS
VRTS
1.1× larger
VRTS
$208.0M
$186.7M
NEO
Growing faster (revenue YoY)
NEO
NEO
+22.0% gap
NEO
11.1%
-10.9%
VRTS
Higher net margin
VRTS
VRTS
74.1% more per $
VRTS
16.3%
-57.9%
NEO
Faster 2-yr revenue CAGR
NEO
NEO
Annualised
NEO
6.5%
-3.2%
VRTS

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
NEO
NEO
VRTS
VRTS
Revenue
$186.7M
$208.0M
Net Profit
$-108.0M
$33.9M
Gross Margin
43.3%
Operating Margin
46.9%
19.1%
Net Margin
-57.9%
16.3%
Revenue YoY
11.1%
-10.9%
Net Profit YoY
42.0%
-14.2%
EPS (diluted)
$-0.13
$5.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NEO
NEO
VRTS
VRTS
Q1 26
$186.7M
Q4 25
$190.2M
$208.0M
Q3 25
$187.8M
$216.4M
Q2 25
$181.3M
$210.5M
Q1 25
$168.0M
$217.9M
Q4 24
$172.0M
$233.5M
Q3 24
$167.8M
$227.0M
Q2 24
$164.5M
$224.4M
Net Profit
NEO
NEO
VRTS
VRTS
Q1 26
$-108.0M
Q4 25
$33.9M
Q3 25
$-27.1M
$31.3M
Q2 25
$-45.1M
$42.7M
Q1 25
$-25.9M
$28.1M
Q4 24
$39.5M
Q3 24
$-17.7M
$49.1M
Q2 24
$-18.6M
$26.0M
Gross Margin
NEO
NEO
VRTS
VRTS
Q1 26
43.3%
Q4 25
43.8%
Q3 25
42.8%
Q2 25
42.6%
Q1 25
43.6%
Q4 24
44.9%
Q3 24
44.6%
Q2 24
44.1%
Operating Margin
NEO
NEO
VRTS
VRTS
Q1 26
46.9%
Q4 25
-7.1%
19.1%
Q3 25
-14.4%
21.7%
Q2 25
-26.3%
21.5%
Q1 25
-16.6%
16.8%
Q4 24
-10.7%
21.7%
Q3 24
-12.6%
24.3%
Q2 24
-13.3%
19.7%
Net Margin
NEO
NEO
VRTS
VRTS
Q1 26
-57.9%
Q4 25
16.3%
Q3 25
-14.4%
14.5%
Q2 25
-24.9%
20.3%
Q1 25
-15.4%
12.9%
Q4 24
16.9%
Q3 24
-10.5%
21.6%
Q2 24
-11.3%
11.6%
EPS (diluted)
NEO
NEO
VRTS
VRTS
Q1 26
$-0.13
Q4 25
$5.15
Q3 25
$4.65
Q2 25
$6.12
Q1 25
$4.05
Q4 24
$4.65
Q3 24
$5.71
Q2 24
$2.43

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NEO
NEO
VRTS
VRTS
Cash + ST InvestmentsLiquidity on hand
$146.1M
Total DebtLower is stronger
$390.0M
Stockholders' EquityBook value
$828.8M
$934.0M
Total Assets
$1.3B
$4.3B
Debt / EquityLower = less leverage
0.42×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NEO
NEO
VRTS
VRTS
Q1 26
$146.1M
Q4 25
$159.6M
Q3 25
$164.1M
Q2 25
$154.7M
Q1 25
$346.2M
Q4 24
$367.0M
Q3 24
$362.0M
Q2 24
$355.1M
Total Debt
NEO
NEO
VRTS
VRTS
Q1 26
Q4 25
$341.9M
$390.0M
Q3 25
$390.6M
Q2 25
$231.3M
Q1 25
$231.7M
Q4 24
$541.1M
$232.1M
Q3 24
$237.5M
Q2 24
$247.6M
Stockholders' Equity
NEO
NEO
VRTS
VRTS
Q1 26
$828.8M
Q4 25
$836.6M
$934.0M
Q3 25
$838.3M
$918.7M
Q2 25
$854.0M
$896.4M
Q1 25
$888.3M
$893.7M
Q4 24
$902.3M
$897.5M
Q3 24
$908.2M
$889.0M
Q2 24
$915.9M
$868.7M
Total Assets
NEO
NEO
VRTS
VRTS
Q1 26
$1.3B
Q4 25
$1.4B
$4.3B
Q3 25
$1.4B
$3.9B
Q2 25
$1.4B
$3.7B
Q1 25
$1.6B
$3.7B
Q4 24
$1.6B
$4.0B
Q3 24
$1.6B
$3.6B
Q2 24
$1.6B
$3.6B
Debt / Equity
NEO
NEO
VRTS
VRTS
Q1 26
Q4 25
0.41×
0.42×
Q3 25
0.43×
Q2 25
0.26×
Q1 25
0.26×
Q4 24
0.60×
0.26×
Q3 24
0.27×
Q2 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NEO
NEO
VRTS
VRTS
Operating Cash FlowLast quarter
$-8.1M
$-67.2M
Free Cash FlowOCF − Capex
$-74.1M
FCF MarginFCF / Revenue
-35.6%
Capex IntensityCapex / Revenue
3.3%
Cash ConversionOCF / Net Profit
-1.99×
TTM Free Cash FlowTrailing 4 quarters
$100.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NEO
NEO
VRTS
VRTS
Q1 26
$-8.1M
Q4 25
$1.3M
$-67.2M
Q3 25
$8.9M
$108.3M
Q2 25
$20.3M
$75.8M
Q1 25
$-25.3M
$-3.8M
Q4 24
$9.8M
$1.8M
Q3 24
$9.2M
$69.1M
Q2 24
$13.9M
$70.0M
Free Cash Flow
NEO
NEO
VRTS
VRTS
Q1 26
Q4 25
$-6.5M
$-74.1M
Q3 25
$570.0K
$106.9M
Q2 25
$14.0M
$74.2M
Q1 25
$-29.8M
$-6.8M
Q4 24
$-1.8M
$-3.8M
Q3 24
$-1.6M
$68.7M
Q2 24
$814.0K
$68.6M
FCF Margin
NEO
NEO
VRTS
VRTS
Q1 26
Q4 25
-3.4%
-35.6%
Q3 25
0.3%
49.4%
Q2 25
7.7%
35.2%
Q1 25
-17.8%
-3.1%
Q4 24
-1.0%
-1.6%
Q3 24
-0.9%
30.3%
Q2 24
0.5%
30.6%
Capex Intensity
NEO
NEO
VRTS
VRTS
Q1 26
Q4 25
4.1%
3.3%
Q3 25
4.4%
0.7%
Q2 25
3.5%
0.7%
Q1 25
2.7%
1.4%
Q4 24
6.7%
2.4%
Q3 24
6.4%
0.2%
Q2 24
8.0%
0.6%
Cash Conversion
NEO
NEO
VRTS
VRTS
Q1 26
Q4 25
-1.99×
Q3 25
3.45×
Q2 25
1.77×
Q1 25
-0.13×
Q4 24
0.04×
Q3 24
1.41×
Q2 24
2.69×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

NEO
NEO

Segment breakdown not available.

VRTS
VRTS

Open End Funds$68.9M33%
Retail Separate Accounts$51.3M25%
Institutional Accounts$39.6M19%
Administration And Shareholder Service Fees$18.4M9%
Closed End Funds$15.9M8%
Distribution And Service Fees$12.3M6%

Related Comparisons